Floatz logo

Fadraciclib

Myelodysplastic Syndrome

Cyclacel Pharmaceuticals, Inc.Phase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

315 Active assets in the Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
Idarubicine
OHSU Knight Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Fadraciclib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
42 / 100
View asset →
Solid Tumor, AdultDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →